Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143572 · ClinicalTrials.gov registry record · Phase 1
Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease
A Phase 1 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT00143572 is a Phase 1 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 16 participants.
The verdict
NCT00143572, a Phase 1 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to estimate the MTD of Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months.
Interventions
- DRUG Magnesium Pidolate, Hydroxyurea
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2004-11 |
| Est. Completion | 2008-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00143572
The ClinicalTrials.gov registry entry for NCT00143572 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Magnesium Pidolate, Hydroxyurea is the first listed.
NCT00143572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00143572 about?
NCT00143572 is a clinical study titled "Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease". The purpose of this study is to estimate the MTD of Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months.
What is the current status of trial NCT00143572?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2004-11. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00143572?
The interventions under investigation include: Magnesium Pidolate, Hydroxyurea (DRUG).
Who is sponsoring clinical trial NCT00143572?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.